Literature DB >> 23329076

Risk of cardiovascular disorders in psoriasis patients: current and future.

Ingrid L D Tablazon1, Amir Al-Dabagh, Scott A Davis, Steven R Feldman.   

Abstract

Psoriasis is an inflammatory autoimmune disease that affects the skin. Recently, psoriasis and its consequential lifestyle and dietary habits have been associated with increased risks for cardiovascular diseases. This article discusses the connection between cardiovascular disorders and psoriasis and the effects of available treatment options on cardiovascular risk. A PubMed search revealed 11 articles that were analyzed for information regarding this association, its effects, and potential courses of treatment. Both the presence and severity of psoriasis increases the risk for cardiovascular disorders and co-morbidities. Forty percent of psoriasis patients met metabolic syndrome criteria as compared with 23 % of non-psoriasis control subjects. Rate ratios for atrial fibrillation are correlated with the severity of psoriasis; patients with severe and mild psoriasis produced rate ratios of 1.63 and 1.31, respectively. Studies also show an increase in the risks for myocardial infarction, atherosclerosis, ischemic stroke, and other cardiovascular disorders. The exact mechanisms behind this affiliation are still uncertain; however, the psychological and physiological effects of psoriasis and the overlapping pathogenesis behind atherosclerosis and psoriasis may play a role. Since the risk for cardiovascular disorders increases with the presence and severity of psoriasis, psoriasis treatment should not only address the disease and its symptoms, but also its co-morbidities. Recent National Psoriasis Foundation (NPF) guidelines have provided recommendations for psoriasis patient care. Histories of co-morbidities, screenings for potential diseases, increased exercise, decreased alcohol consumption, and smoking cessation should be implemented. Unfortunately, while there are data for the increased risk for cardiovascular diseases within psoriasis patients, there are presently no data stating that increasing cardiovascular screening rates in patients produces a significant difference.

Entities:  

Mesh:

Year:  2013        PMID: 23329076     DOI: 10.1007/s40257-012-0005-5

Source DB:  PubMed          Journal:  Am J Clin Dermatol        ISSN: 1175-0561            Impact factor:   7.403


  8 in total

1.  Effectiveness of Lipid-Lowering Statin Therapy in Patients With and Without Psoriasis.

Authors:  William C Ports; Rana Fayyad; David A DeMicco; Rachel Laskey; Robert Wolk
Journal:  Clin Drug Investig       Date:  2017-08       Impact factor: 2.859

2.  Psoriasis and cardiovascular disorders: association or epiphenomenon? Meta-analysis of observational studies.

Authors:  Saumya Choudhary; Rachana Patel; Dibyabhaba Pradhan; Ravi Deval; Harpreet Singh; George Thomas; Arun Kumar Jain
Journal:  3 Biotech       Date:  2020-02-07       Impact factor: 2.406

3.  Dietary salt promotes neurovascular and cognitive dysfunction through a gut-initiated TH17 response.

Authors:  Giuseppe Faraco; David Brea; Lidia Garcia-Bonilla; Gang Wang; Gianfranco Racchumi; Haejoo Chang; Izaskun Buendia; Monica M Santisteban; Steven G Segarra; Kenzo Koizumi; Yukio Sugiyama; Michelle Murphy; Henning Voss; Joseph Anrather; Costantino Iadecola
Journal:  Nat Neurosci       Date:  2018-01-15       Impact factor: 24.884

Review 4.  Psoriasis: classical and emerging comorbidities.

Authors:  Maria de Fátima Santos Paim de Oliveira; Bruno de Oliveira Rocha; Gleison Vieira Duarte
Journal:  An Bras Dermatol       Date:  2015 Jan-Feb       Impact factor: 1.896

5.  Association between Psoriasis Vulgaris and Coronary Heart Disease in a Hospital-Based Population in Japan.

Authors:  Masayuki Shiba; Takao Kato; Moritoshi Funasako; Eisaku Nakane; Shoichi Miyamoto; Toshiaki Izumi; Tetsuya Haruna; Moriaki Inoko
Journal:  PLoS One       Date:  2016-02-24       Impact factor: 3.240

6.  Neurodegenerative disorders, bullous pemphigoid and psoriasis: a comparative study in ethnic Poles indicates that Parkinson's disease is more relevant to bullous pemphigoid.

Authors:  Paweł Bartkiewicz; Justyna Gornowicz-Porowska; Paweł P Pietkiewicz; Anna Świrkowicz; Monika Bowszyc-Dmochowska; Marian Dmochowski
Journal:  Postepy Dermatol Alergol       Date:  2017-02-07       Impact factor: 1.837

Review 7.  Management of psoriasis as a systemic disease: what is the evidence?

Authors:  N J Korman
Journal:  Br J Dermatol       Date:  2019-10-15       Impact factor: 9.302

8.  Associations between cardiovascular risk factors and psoriasis in Iran.

Authors:  Mahmoud Farshchian; Akram Ansar; Mohammadreza Sobhan
Journal:  Clin Cosmet Investig Dermatol       Date:  2015-08-10
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.